NCT03236792View on ClinicalTrials.gov

Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 12, 2017

Primary Completion Date

September 20, 2022

Study Completion Date

September 20, 2022

Conditions
AL Amyloidosis
Interventions
DRUG

Ixazomib

3 mg or 4mg of Ixazomib will be taken orally on days 1, 8, and 15 of a 28-day cycle

DRUG

Cyclophosphamide

300, 400, or 500 mg of oral Cyclophosphamide on days 1, 8, and 15 of a 28-day cycle

DRUG

Dexamethasone

20 mg of oral Dexamethasone on days 1, 8, 15, 22 in a 28-day cycle

Trial Locations (3)

10029

Icahn School of Medicine at Mount Sinai, New York

10065

Memorial Sloan Kettering Cancer Center, New York

Weill Cornell Medicine, New York

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT03236792 - Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis | Biotech Hunter | Biotech Hunter